Curium Announces Last Patient Enrolled in Their Phase 1/2 SOLAR Clinical Trial Imaging Men with Histologically-Proven Metastatic Prostate Cancer Using Copper Cu 64 PSMA I&T.
PARIS, May 23, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has completed enrollment in its USA-led SOLAR Phase 1/2 study evaluating the safety, biodistribution, and image quality of Copper Cu64 PSMA I&T injection to detect metastatic prostate cancer in PET imaging.
Michael Patterson, CEO – North America at Curium commented, “We are pleased to complete the Phase 1/2 SOLAR study enrollment ahead of schedule. We are excited to use Curium’s centralized Copper-64 production capabilities and our industry leading distribution network in upcoming Phase 3 trials. As we work globally to redefine the experience of cancer through our trusted legacy in nuclear medicine, we remain focused on driving innovation to improve the lives of more than 14 million patients each year.”
Sakir Mutevelic, MD, MSc, Chief Medical Officer at Curium commented, “Completing the enrollment of patients for the SOLAR study is not only an important milestone for the study itself, but also a testament to the hard work and dedication of our investigators. We are very pleased with the clinical development progress of Cu-64-PSMA-I&T. After the completion of our analysis, we look forward to collaborating with our future investigators to start our Phase 3 program looking into the use of Cu-64-PSMA-I&T in patients with prostate cancer for initial staging and also for biochemical recurrence.”
Prostate cancer is the most common cancer and the second leading cause of cancer death among men in the United States. There will be an estimated 288,000 new cases of prostate cancer in 2023.
For more information about the SOLAR trial: https://www.curiumpharma.com/resources/current-clinical-trials/solar-clinical-trial/
To locate a clinical trial site or contact Curium’s SOLAR clinical trial team: firstname.lastname@example.org
Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service.
With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit www.curiumpharma.com
For more information:
VP, Head of Global Communications
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
AccuStem Sciences, Inc. Announces Collaboration Agreement with University Hospitals6.6.2023 07:00:00 CEST | Press release
LONDON and PHOENIX, Ariz., June 06, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, today announced the establishment of a joint clinical collaboration agreement with University Hospitals. Per the terms of this agreement, University Hospitals will provide tissue samples with clinical outcomes to AccuStem for research purposes. The scope of the agreement covers a multitude of different cancers but will initially focus on breast cancer cases to support further validation of the StemPrintER test. The goal of the initial project is to build on the strong foundation of data for StemPrintER by demonstrating additional clinical utility beyond identifying patients’ risk of recurrence. This next step is critical for women with early stage breast cancer because there are many tests to determine the need for chemotherapy but there are no genomic tools to inform decisions earlier in the c
TGS Expands Multi-Client Coverage for Malvinas 3D Offshore Argentina6.6.2023 07:00:00 CEST | Press release
OSLO, Norway (6 June 2023) – TGS, a leading global provider of energy data and intelligence, announced today Malvinas 3D Phase III, an expansion of its multi-client 3D coverage in Malvinas Basin offshore Argentina. The company plans to acquire a ~7,500 square kilometer 3D seismic survey and upon completion, TGS will have built a 3D library of 25,000 square kilometers in the Malvinas Basin. Kristian Johansen, TGS CEO, commented, "We are pleased to announce the expansion of our multi-client coverage for the Malvinas 3D project offshore Argentina. This project demonstrates our commitment to continuously providing our clients with the most up-to-date and accurate information to drive their exploration efforts. By leveraging our advanced seismic imaging technology, we aim to unlock the full potential of this region and support the energy industry in its pursuit of sustainable energy resources." Acquisition of Malvinas 3D Phase III is expected to commence by early 2024. This project is suppo
Santhera Publishes Agenda for its Annual General Meeting6.6.2023 07:00:00 CEST | Press release
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, June6, 2023 – Santhera Pharmaceuticals (SIX: SANN) today published the agenda for its Annual General Meeting (AGM), which will be held on June 27, 2023, at 10:00 CESTat Haus der Wirtschaft, Hardstrasse 1, 4133 Pratteln, Switzerland. The invitation to the Annual General Meeting with agenda items and explanations can be viewed on Santhera’s website at https://www.santhera.com/share-bondholder-meetings. Selected agenda items Elections The Board of Directors proposes the re-election of Thomas Meier, PhD, and Philipp Gutzwiller as members of the BoD until the end of the AGM 2024. Additionally, Thomas Meier, PhD, is nominated for re-election as the Chairman of the BoD. Patrick Vink, member of Santhera’s Board and Chairman of the Compensation Committee since 2017, decided not to stand for re-electi
Idorsia has entered into exclusive negotiations with regard to a prospective strategic transaction for its Asia Pacific (ex-China) operations for up to CHF 400 million6.6.2023 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – June06, 2023 Idorsia Ltd (SIX: IDIA) today announced that it has entered into exclusive negotiations with an undisclosed party regarding its operating businesses in the Asia Pacific (ex-China) region, including selected license rights to products from Idorsia’s portfolio in those territories, for a total consideration of up to CHF 400 million. This prospective strategic transaction is subject to completion of satisfactory due diligence and legal documentation. Further announcements will be made as appropriate. André C. Muller, Chief Financial Officer of Idorsia, added: “This prospective strategic transaction would allow Idorsia to realize the significant value we have created in the region, and would extend our cash runway, while maintaining relationships for the future development and commercialization of our pipeline programs in the region. I would expect the potential transaction to be completed during July, subject
Ai-Media to Launch AI-Powered Automatic Captioning Solution to Asian Market at BroadcastAsia6.6.2023 06:00:00 CEST | Press release
SYDNEY, Australia, June 06, 2023 (GLOBE NEWSWIRE) -- Ai-Media, the leader in technology-driven live captioning, transcription, and translation solutions, is excited to announce its presence at BroadcastAsia in Singapore, where it will unveil its ground-breaking LEXI 3.0 automatic captioning solution to the Asian market. Previously launched to the North American market at NAB Show 2023, LEXI 3.0 is the new and improved version of Ai-Media’s flagship automatic captioning solution. Powered by AI, LEXI 3.0 is the world’s most accurate and advanced automatic captioning solution, delivering results that rival human captions at a fraction of the cost. During the BroadcastAsia, Ai-Media will also showcase its comprehensive range of captioning technology that boasts seamless integration with LEXI 3.0. Among the featured products is the new LEXI Viewer, an innovative HD-SDI device that empowers event organizers to effortlessly enhance accessibility by streaming captions to in-venue displays. Add